Jove
Visualize
Contact Us

Related Concept Videos

Case Studies01:22

Case Studies

There are many research methods available to psychologists in their efforts to understand, describe, and explain behavior and the cognitive and biological processes that underlie it.
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Methods of Documentation V: CBE01:23

Methods of Documentation V: CBE

Charting by Exception, or CBE, is a method of documentation used in healthcare, particularly in nursing, that focuses on documenting only significant or abnormal findings rather than recording every detail. This approach aims to streamline the documentation process, improve efficiency, and ensure that healthcare providers can quickly identify deviations from normalcy in patient assessments.
In CBE, healthcare professionals establish predefined standards of practice that define what constitutes...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Preacinetobactin not acinetobactin is essential for iron uptake by the BauA transporter of the pathogen <i>Acinetobacter baumannii</i>.

eLife·2018
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: May 13, 2026

Development of a Polymicrobial Colony Biofilm Model to Test Antimicrobials in Cystic Fibrosis
07:16

Development of a Polymicrobial Colony Biofilm Model to Test Antimicrobials in Cystic Fibrosis

Published on: September 20, 2024

Ceftobiprole - a case study.

Malcolm Gp Page1

  • 1Head of Biology, Basilea Pharmaceutica Ltd, Grenzacherstrasse 487, PO Box, CH-4005 Basel, Switzerland. malcolm.page@basilea.com.

Expert Opinion on Drug Discovery
|March 19, 2013
PubMed
Summary

Ceftobiprole medocaril shows promise for treating serious infections like MRSA-related skin issues and pneumonia. Clinical trials indicate high cure rates and good tolerability, suggesting a valuable new antibiotic option.

Area of Science:

  • Infectious Diseases
  • Pharmacology
  • Bacteriology

Background:

  • Ceftobiprole medocaril is a cephalosporin prodrug under investigation for treating serious bacterial infections.
  • Key targets include methicillin-resistant Staphylococcus aureus (MRSA) and penicillin-resistant Streptococcus pneumoniae (PRSP).

Purpose of the Study:

  • To evaluate the efficacy and safety of ceftobiprole medocaril in treating complicated skin and skin-structure infections (cSSSIs) and hospital-acquired pneumonia (HAP).
  • To assess its activity against Gram-positive and Gram-negative pathogens, including resistant strains.

Main Methods:

  • Phase III clinical trials (STRAUSS 1 and STRAUSS 2) were conducted to assess ceftobiprole medocaril.
  • Microbiological studies evaluated its spectrum of activity against various bacterial pathogens.

More Related Videos

Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis
05:56

Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis

Published on: August 29, 2025

Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes
03:53

Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes

Published on: April 19, 2024

Related Experiment Videos

Last Updated: May 13, 2026

Development of a Polymicrobial Colony Biofilm Model to Test Antimicrobials in Cystic Fibrosis
07:16

Development of a Polymicrobial Colony Biofilm Model to Test Antimicrobials in Cystic Fibrosis

Published on: September 20, 2024

Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis
05:56

Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis

Published on: August 29, 2025

Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes
03:53

Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes

Published on: April 19, 2024

Main Results:

  • Top-line results from the STRAUSS 1 trial for cSSSI demonstrated a high cure rate and favorable tolerability.
  • The antibiotic exhibits potent bactericidal activity against MRSA and PRSP.
  • Broad-spectrum activity was observed against important Gram-positive and Gram-negative pathogenic bacteria.

Conclusions:

  • Ceftobiprole medocaril offers a promising therapeutic option for infections caused by resistant bacteria.
  • It combines established cephalosporin advantages with an enhanced spectrum of activity.
  • Further investigation in trials like STRAUSS 2, including diabetic foot infections, is ongoing.